Overview

Hepatitis C in Renal Transplant Recipients

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Prof. Dr. Alice Schmidt
Treatments:
Cyclosporine
Cyclosporins
Tacrolimus
Criteria
Inclusion Criteria:

- written informed consent

- prior renal transplantation

- current tacrolimus-based immunosuppressive regimen

- hepatitis C-infection

- age 18-70 years

Exclusion Criteria:

- current hemodialysis or peritoneal dialysis

- pregnancy or breastfeeding

- known contraindication for cyclosporine A-treatment